Economic outcomes: Costs due to treatment, as defined by each study (long term) · patients with schizophrenia
1 finding from 1 review
Efficacy: change in scores from baseline to endpoint (12 weeks) on symptom rating scales in the treatment of manic and mixed episodes Lower scores indicate improvement · adults with acute affective episodes in bipolar disorder
1 finding from 1 review
Change in depressive symptoms · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Response to treatment with topiramate. Number of participants experiencing a 50% reduction or greater in mean score from baseline to end of treatment on symptom rating scales in manic and mixed episodes · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
> 50% reduction in depressive symptoms · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: change in scores from baseline to endpoint (12 weeks) on symptom rating scales in the treatment of manic and mixed episodes Lower scores indicate improvement · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in depressive symptoms · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Response to treatment with topiramate. Number of participants experiencing a 50% reduction or greater in mean score from baseline to end of treatment on symptom rating scales in manic and mixed episodes · adults with acute affective episodes in bipolar disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
> 50% reduction in depressive symptoms · adults with acute affective episodes in bipolar disorder
It is very uncertain whether topiramate as add‐on therapy changes response to treatment with topiramate. Number of participants… compared with alternative drug (very low certainty).
1 finding from 1 review
Total effectiveness rate with subgroup analysis ‐ individualised treatment Clinician's rating · atopic eczema
CHM may leads to higher total effectiveness rate with subgroup analysis ‐ individualised… compared with drugs (low certainty).
1 finding from 1 review
Total effectiveness rate with subgroup analysis ‐ non‐individualised treatment Clinician's rating · atopic eczema
It is very uncertain whether CHM changes total effectiveness rate with subgroup analysis ‐ non‐individualised… compared with drugs (very low certainty).
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Participant‐reported pain relief of 50% or greater · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Patient Global Impression of Change much or very much improved · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Any pain‐related outcome indicating some improvement · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Number experiencing adverse effects · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Number of participants experiencing any serious adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Overall survival† · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower overall survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.6 [0.45, 0.81]
324 participants
Moderate
Progression‐free survival · people with cutaneous melanoma
Anti‐angiogenic drugs plus chemotherapy probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.69 [0.52, 0.92]
324 participants
Moderate